Expert-backed testing to monitor therapy, assess risk, and identify misuse
Mayo Clinic Laboratories’ controlled substance monitoring profiles were developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic and are consistent with laboratory medicine practice guidelines established by the American Association for Clinical Chemistry (AACC),2 which were endorsed by the American Academy of Pain Medicine (AAPM). The results of these assays can be used to guide pharmacotherapy decisions while ensuring prescribing adherence to federal and state guidelines through compliance monitoring.
Commonly prescribed benzodiazepines (e.g., alprazolam, clonazepam), opioids (e.g., hydrocodone, oxycodone, methadone), and stimulants (e.g., methylphenidate, amphetamine) present challenges for clinicians due to their high risk of misuse, abuse, and diversion.1
Identifies drug use involving alcohol, amphetamines, barbiturates, benzodiazepines, cocaine, opioids, PCP, and COOH-THC.
Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are direct biomarkers of ethanol and are detectable in urine for up to five days following alcohol consumption. EtG/EtS results should be interpreted in the context of all available clinical and behavioral information.
Includes specimen validity testing.
Results reported with interpretative comments.
To better meet the needs of our clients, this profile is available with the quantification of presumptive positive results (Mayo ID: CSMPU) or without (Mayo ID: CSMHU) for the drug classes screened by immunoassay (i.e., barbiturates, cocaine, and THC).
Identifies drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine (PCP) and carboxy-tetrahydrocannabinol (COOH-THC).
Includes specimen validity testing.
Results reported with interpretative comments.
Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU).
References
Preuss CV, Kalava A, King KC. Prescription of controlled substances: benefits and risks. Treasure Island, FL: StatPearls Publishing; 2019.
Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline — Using Clinic Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. J Applied Lab Med. 2018;2(4):489-526.
INTERESTED IN LEARNING MORE?
Fill out the form below and one of our specialists will be in touch.
